New Phase I clinical trial protocol submitted to FDA to treat subjects with xerostomia after XRT for Head and Neck Cancer using “fresh” interferon-γ activated MSCs at UW Health
A new clinical trial protocol to be covered under an investigator-sponsored IND held by UW Program for Advanced for Advanced Cell Therapy was submitted to the FDA this week. Randall Kimple MD, PhD, UW Associate …
January 10, 2023UW PACT connects with FDA CATT to advance novel UW-Madison T-cell CRISPR methodology.
UW Program for Advanced Cell Therapy connects with FDA CBER Advanced Technologies Team (CATT) to advance clinical development of novel University of Wisconsin-Madison T-cell CRISPR methodology. Ross Meyers, Director of Cell Manufacturing of UW Program for Advanced Cell Therapy (PACT) …
December 14, 2022UW Program for Advanced Cell Therapy Director of R&D secures membership to UW Carbone Cancer Center
On November 16 2022, Andrea Pennati secured associate membership within the UW Carbone Cancer Center in the UW School of Medicine and Public Health. He has been appointed as a member of the UWCCC’s Developmental Therapeutics Program where innovations in …
November 22, 2022PACT Intern Completes MS in Applied Drug Development – joins manufacturing team
Xingyi Tang completed her Master of Science in the University of Wisconsin-Madison, School of Pharmacy Applied Drug Development program. Ms. Tang chose to complete the internship portion of her requirements in the UW Program for Advanced Cell Therapy. …
November 16, 2022Pilot Study of autologous MSCs for Radiation-Induced Xerostomia (Dry Mouth) in Head and Neck Cancer Patients Completed
The UW Program for Advanced Cell Therapy has completed enrollment for the pilot MARSH (Marrow-derived Autologous Stromal cells for the Restauration of Salivary Hypofunction) clinical trial. Six patients with radiation-induced Xerostomia (Dry Mouth) were treated in the …
November 13, 2022- More News
Integrated personalized cell technologies for improving health outcomes in children and adults